Anesiva Inc: Premium Company Profile

Anesiva (previously Corgentech), based in South San Francisco, California, is a late stage biotechnology company with two product candidates: Zingo and Altea for the potential treatment of various pain management indications. The company merged with AlgoRX, a privately-held pain management company, to expand its pipeline portfolio.

Report Highlights
Anesiva is focused on developing and commercializing novel treatments for pain management. It is preparing to launch Zingo, its approved product, through its sales force and co-promoter in the US. Altea, its second product candidate in Phase II, is being studied for the treatment of post surgery pain management. Anesiva recognized revenues as collaboration payments and license fees from Bristol Meyers Squibb and Lumen Therapeutics. Its total revenues declined from $0.15 million in 2002 to $0.09 million in 2006. Moreover, it did not record revenues in 2004 and 2005. Anesiva expects to generate all of its revenues during 2006-2010 from sales of Zingo. The product is forecasted to contribute $114 million by 2010 to the company’s coffers.
[Fade out the market survey infos]

Overview 1
Catalyst 1
Summary 1
Company Structure 6
Company Overview and Key Facts 6
Business Description 7
History 9
Locations and Subsidiaries 11
Company Financials 12
Stock Market Performance 12
P&L 13
Balance Sheet 16
Cash Flow 16
Business Segment Performance 17
Products & Services 18
Pipeline Products 18
AC Forecast Product Sales 19
Competitors and Strategic Business Relationships 20
Key Competitors 20
Key Suppliers 21
Key Clients 21
Shareholding Structure 23
Strategy 24
Company View 24
Corporate Strategy 26
SWOT Analysis 27
Overview 27
Strengths 28
Weaknesses 29
Opportunities 30
Threats 31
Value Chain Analysis 32
Overview 32
Discovery and Product Development 33
Manufacturing 33
Sales 33
Scorecard 34
Overview 34
Scorecard Analysis 35
Key Employees 36
List of Key Employees 36
Key Employee Biographies 37
Financial and Operational Overview 47
Financial and Operational Overview 47
Appendix 49
Ask the analyst 49
Datamonitor consulting 49
Disclaimer 49
[Fade out table of contents]

Table 1: Anesiva- Key Facts 6
Table 2: Anesiva– Locations and Subsidiaries 11
Table 3: Anesiva- Year-End Share Price and Market Capitalization, 2002-2006 ($) 12
Table 4: Anesiva- Key Events Impacting Share Price Performance 12
Table 5: Anesiva- Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) 13
Table 6: Anesiva- Operating Cost Ratio Analysis, 2002-2006 (% of total revenues) 15
Table 7: Anesiva- Balance Sheet, 2002-2006 ($ Mn) 16
Table 8: Anesiva- Cash Flow, 2002-2006 ($ Mn) 16
Table 9: Anesiva- Key Strategic Revenues, 2002-2006 ($ Mn) 17
Table 10: Anesiva- In-house Pipeline Products 18
Table 11: Anesiva- Key Strategic Revenues, 2006-2010 ($ Mn) 19
Table 12: Anesiva- Key Competitors 20
Table 13: Anesiva- Key Suppliers 21
Table 14: Anesiva- Key Clients 22
Table 15: Anesiva- Key Shareholders 23
Table 16: Anesiva - SWOT Analysis Summary 27
Table 17: Anesiva– Value Chain Analysis 32
Table 18: Anesiva- Scorecard 34
Table 19: Anesiva- Key Employees 36
Table 20: Anesiva- Financial and Operational Overview 47
Figure 1: Anesiva- Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) 14
[Fade out list of tables / figures]